Prediction of antiviral therapy response
AssigneeNovartis Forschungsstiftung, Zweigniederlassung Friedrich Mischer Institute for Biomedical Researc
InventorsWitold Filipowicz, Markus Heim, Jacek Krol, Ilona Krol, Magdalena Filipowicz
Life of this patent
Estimating the term…
Abstract
The application relates to methods for determining whether or not antiviral therapies will be effective. In particular, the present application provides a method using miRNA, e.g. miR-122 or miR-296-5p, for determining the likelihood that a subject having a viral infection of the liver will be responsive to antiviral therapy that includes stimulation of Interferon (IFN) activity, and kits for the performance of said determination.
Claims15
A method for determining the likelihood that a subject having a viral infection of the liver will be responsive to antiviral therapy comprising Interferon (IFN) treatment, the method comprising:
- (a) analyzing a tissue sample from the subject having the viral infection for the level of expression of miR-122 and/or miR-296-5p and,
- (b) comparing the level of expression of miR-122 and/or miR-296-5p in the tissue sample from the subject having the viral infection to the level of expression of miR-122 and/or miR-296-5p in a control tissue sample from a subject without viral infection,
- wherein a significantly lower level of miR-122 in the sample from the subject having the viral infection as compared to the level of miR-I22 in the control sample from the subject without viral infection indicates that the subject having the viral infection is not likely to respond to said antiviral therapy;
- and
- wherein a significantly higher level of miR-296-5p in the sample from the subject having the viral infection as compared to the level of miR-296-5p in the control sample from the subject without viral infection indicate that the subject having the viral infection is not likely to respond to said antiviral therapy.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A kit comprising a specific binding molecule for analyzing the level of expression of miR-122 and/or miR-296-5p selected from the group consisting of an oligonucleotide probe, antibody, aptamer, binding protein and small molecule.
Dependencies are inferred from the claim text.